HEOR Staff Writer

Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
FDA Guidance on Overall Survival Assessment in Oncology Trials
Eli Lilly’s Innovation Statement: Advocating Drug Pricing Reforms
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Econ...